British Journal of Sexual Medicine

Reference list

Pisipati S, Pearce I. Peyronie’s disease, or induratio penis plastica – an overview. BJSM 2008; 31.4: 4–7.

1. de la Peyronie F. Sur quelques obstacles qui s’opposent à l’éjaculation naturelle de la semence. Mem Acad Chir 1743; 1: 425.

2. Lindsay MB, Schain DM, Grambsch P et al. The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991; 146: 1007–1009.

3. Schwarzer U, Sommer F, Klotz T et al. The prevalence of Peyronie’s disease: results of a large survey. BJU Int 2001; 88: 727–730.

4. Chilton CP, Castle WM, Westwood CA, Pryor JP. Factors associated in the aetiology of Peyronie’s Disease. Br J Urol 1982; 54: 748–750.

5. Pryor JP, Ralph DJ. Clinical presentations of Peyronie’s disease. Int J Impot Res 2002; 14: 414–417.

6. Furey CA. Peyronie’s disease: treatment by the local injection of meticortelone and hydrocortisone. J Urol 1957; 77: 251–266.

7. Somers KD, Dawson DM. Fibrin deposition in Peyronie’s disease plaque. J Urol 1997; 157: 311–315.

8. Smith BH. Subclinical Peyronie’s disease. Am J Clin Pathol 1969; 52: 385–390.

9. Burford CE, Glen JE, Burford EH. Fibrous cavernositis: further observation with report of 31 additional cases. J Urol 1943; 49: 350–356.

10. Bystrom J, Rubio C. Induratio penis plastica: clinical features and aetiology. Scand J Urol Nephrol 1976; 10: 12–20.

11. Smith BH. Peyronie’s disease. Am J Clin Pathol 1966; 45: 670–678.

12. Chesney J. Peyronie’s disease. Br J Urol 1975; 47: 209–218.

13. Hinmann F. Etiological factors in Peyronie’s disease. Urol Int 1980; 35: 407–413.

14. Ralph DJ, Minhas S. The management of Peyronie’s disease. BJU Intl 2004; 93: 208–215.

15. Nyberg LM Jr, Bias WB, Hochbert MC, Walsh PC. Identification of an inherited form of Peyronie’s disease with autosomal dominant inheritance and association with Dupuytren’s contracture and histocompatibility B7 cross-reacting antigens. J Urol 1982; 128: 48–51.

16. Ralph DJ, Schwartz G, Moore W et al. The genetic and bacteriological aspects of Peyronie’s disease. J Urol 1997; 157: 291–294.

17. Rompel R, Weidner W, Mueller-Eckhardt G. HLA association of idiopathic Peyronie’s disease: an indication of autoimmune phenomenon in aetiopathogenesis? Tissue Antigens 1991; 38: 104–106.

18. Nachtsheim DA, Rearden A. Peyronie’s disease is associated with an HLA class II antigen HLA-DQ5, implying an autoimmune aetiology. J Urol 1996; 156: 1330–1334.

19. Stewart S, Alto M, Sandberg L, Colburn KK. Increased serum levels of anti-elastin antibodies in patients with Peyronie’s disease. J Urol 1994; 152: 105–106.

20. Ralph DJ, Mirakian R, Pryor JP, Bottazzo GF. The immunological features of Peyronie’s disease. J Urol 1996; 155: 159–162.

21. Kendirci M, Trost L, Sikka SC, Hellstrom WJ. Diabetes mellitus is associated with severe Peyronie’s disease. BJU Int 2007; 99: 383–386.

22. Davis C Jr. The microscopic pathology of Peyronie’s disease. J Urol 1997; 157: 282–284.

23. Schick V, Bernhards J, Rahle R. Clinical symptomatology and histopathological changes in Peyronie’s disease: a comparative analysis. Aktuelle Urol 2007; 38: 313–319.

24. Ferrini MG, Vernet D, Magee TR et al. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 2002; 6: 283–294.

25. Deveci S, Hopss CV, O’Brien K et al. Defining the clinical characteristics of Peyronie’s disease in young men. J Sex Med 2007; 4: 485–490.

26. Obeyesekera S, Herdiman J, Goh BT. Patient-initiated digital photography in Peyronie’s disease. Int J STD AIDS 2006; 17: 493–494.

27. Kadioglu A, Tefekli A, Erol B et al. A retrospective review of 307 men with Peyronie’s disease. J Urol 2002; 68: 283–294.

28. Amin Z, Patel U, Friedmann EP et al. Colour Doppler and duplex ultrasound assessment of Peyronie’s disease in impotent men. Br J Radiol 1993; 66: 398–402.

29. Pryor JP. Peyronie’s disease and impotence. Acta Urol Belg 1988; 56: 317–321.

30. Ralph DJ, Al-Akraa M, Pryor JP. The Nesbit operation for Peyronie’s disease: 16-year experience. J Urol 1995; 154: 1362–1363.

31. Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP. The treatment of Peyronie’s disease with tamoxifen. Br J Urol 1992; 70: 648–651.

32. Teloken C, Rhoden EL, Grazziotin TM, Da Ros CT, Sogari PR. Tamoxifen versus placebo in the treatment of Peyronie’s disease. J Urol 1999; 162: 2003–2005.

33. Zarafonetis CJD, Horrax TM. Treatment of Peyronie’s disease with potassium para-amino benzoate (POTABA). J Urol 1959; 81: 770–772.

34. Shah PJR, Green NA, Adib RS et al. A multicentre double-blind controlled clinical trial of potassium para-aminobenzoate (POTABA) in Peyronie’s disease. Prog Reprod Biol 1983; 9: 47–60.

35. Scardino PL, Scott WW. The use of tocopherols in the treatment of Peyronie’s disease. Ann NY Acd Sci 1949; 52: 390–401.

36. Pryor JP, Farell CF. Controlled clinical trial of Vitamin E in Peyronie’s disease. Prog Reprod Biol 1983; 9: 41–45.

37. Kadioglu JP, Tefekli A, Koksal T, Usta M, Erol H. Treatment of Peyronie’s disease with oral colchicines: long-term results and predictive parameters of successful outcome. Int J Impot Res 2000; 12: 169–75

38. Levine LA, Goldmann KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol 2002; 168: 621–625.

39. Hellstrom WJ, Kendirci M, Matern R et al. Single-blind, multicenter, placebo-controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 2006; 176: 394–398.

40. Lebret T, Loison G, Herve JM et al. Extracorporeal shock wave therapy in the treatment of Peyronie’s disease: experience with standard lithotripter (siemens-multiline). Urology 2002; 59: 657–661.

41. Srirangam SJ, Manikandan R, Hussain J, Collins GN, O’Reilly PH. Long-term results of extracorporeal shockwave therapy for Peyronie’s disease. J Endourol 2006; 20: 880–884.

42. Taylor J, Forster JA, Browning AJ, Biyani CS. Extracorporeal shockwave therapy for Peyronie’s disease: who benefits? J Endourol 2006; 20: 135–138.

43. Incrocci L, Wijnmaalen A, Slob AK, Hop WC, Levendag PC. Low-dose radiotherapy in 179 patients with Peyronie’s disease: treatment outcome and current sexual functioning. Int J Radiat Oncol Biol Phys 2000; 47: 1353–1356.

44. Niewald M, Wenzlawowicz KV, Fleckenstein J et al. Results of radiotherapy for Peyronie’s disease. Int J Radiat Oncol Biol Phys 2006; 64: 258–262.

45. Glina S, Gelbard MK, Akkus E, Jordan GH, Levine LA. The use of collagenase in the treatment of Peyronie’s disease – M.K. Gelbard, A. Lindner and J.J. Kaufman. J Sex Med 2007; 4: 1209–1213.

46. National Institute for Health and Clinical Excellence. Extracorporeal shockwave therapy for Peyronie’s disease guidance. London: NICE, 2003.

47. El-Sakka AI, Yassin AA. Conservative treatment for Peyronie’s disease: an update. Expert Opin Pharmacother 2008; 9: 53–63.

48. Taylor FL, Levine LA. Non-surgical therapy of Peyronie’s disease. Asian J Androl 2008; 10: 79–87.

49. Perugia G, Liberti M, Vicini P, Colistro F, Gentile V. Role of hyperthermia in the treatment of Peyronie’s disease: a preliminary study. Int J Hyperthermia 2005; 21: 367–374.

50. Jordan GH. Peyronie’s disease: update on medical management and surgical tips. Can J Urol 2007; 14: 69–74.

51. Savoca G, Trombetta C, Ciampalini S et al. Long-term results with Nesbit’s procedure as treatment of Peyronie’s disease. Int J Impot Res 2000; 12: 289–293.

52. Moyano Calvo JL, Sanchez de la Vega J, Giraldez Puig J et al. Our experience with the Nesbit technique for the treatment of Peyronie’s disease. Arch Esp Urol 2006; 59: 511–515.

53. van der Drift DG, Vroege JA, Groenendijk PM et al. The plication procedure for penile curvature. Surgical outcome and postoperative sexual functioning. Urol Int 2002; 69: 120–124.

54. Fazili T, Kouriefs C, Anjum F, Masood S, Mufti GR. Ten year outcome analysis of corporeal placation for Peyronie’s disease. Int Urol Nephrol 2007; 39: 111–114.

55. Devine CJ, Horton CE. Surgical treatment of Peyronie’s disease with a dermal graft. J Urol 1974; 111: 44–49.

56. Austoni E, Colombo F, Mantovani F, Patelli E, Fenice O. [Radical surgery and conservation of erection in Peyronie's disease]. Arch Ital Urol 1995; 67: 359–364.

57. Rolle L, Tamagnone A, Bollito E et al. Could plaque excision surgery with sis graft induce a new fibrotic reaction in la Peyronie’s disease patients? Arch Ital Urol Androl 2007; 79: 167–169.

58. Lue TF, El-Sakka AI. Venous patch graft for Peyronie’s disease. Part I technique. J Urol 1998; 160: 2047–2049.

59. Montorsi F, Salonia A, Maga T et al. Evidence based assessment of long-term results of plaque incision and vein grafting for Peyronie’s disease. J Urol 2000; 163: 1704–1708.

60. Akkus E, Ozkara H, Alici B et al. Incision and venous patch graft in the surgical treatment of penile curvature in Peyronie’s disease. Eur Urol 2001; 40: 531–536.

61. Kadioglu A, Sanli O, Akman T et al. Surgical treatment of Peyronie’s disease: a single centre experience with 145 patients. Eur Urol 2008; 53: 432–439.

62. Knoll LD. Use of small intestinal submucosal graft for the surgical management of Peyronie’s disease. J Urol 2007; 178: 2474–2478.

63. Kadioglu A, Sanli O, Akman T et al. Graft materials in Peyronie's disease surgery: a comprehensive review. J Sex Med 2007; 4: 581–595.

64. Wilson SK, Cleeves MA, Delk JR. Long-term follow-up of treatment for Peyronie’s disease: modelling the penis over an inflatable penile prosthesis. J Urol 2001; 165: 825–829.

Published by Hayward Medical Communications

www.hayward.co.uk